Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMP360 in recurrent Major Depressive Disorder
NCT05733546Phase 2Active, not recruiting
- Sponsor
- COMPASS Pathways
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of COMP360 in major depressive disorder (MDD), sponsored by COMPASS Pathways. Started Jan 2023; status: active, not recruiting.
02
Drugs
COMP360
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05733546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05733546.